Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma

AGATA MARJANSKA, PRZEMYSLAW GALAZKA, MICHAL MARJANSKI, MARIUSZ WYSOCKI and JAN STYCZYNSKI
Anticancer Research July 2019, 39 (7) 3945-3947; DOI: https://doi.org/10.21873/anticanres.13547
AGATA MARJANSKA
1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agata.marjanska{at}wp.pl
PRZEMYSLAW GALAZKA
2Department of General and Oncological Surgery for Children and Adolescents, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAL MARJANSKI
3Clinical Oncology Department, Oncology Center, Bydgoszcz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIUSZ WYSOCKI
1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAN STYCZYNSKI
1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 39 no. 7 3945-3947
DOI 
https://doi.org/10.21873/anticanres.13547
PubMed 
31262925

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received April 12, 2019
  • Revision received May 28, 2019
  • Accepted June 3, 2019
  • Published online July 1, 2019.

Copyright & Usage 
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. AGATA MARJANSKA1⇑,
  2. PRZEMYSLAW GALAZKA2,
  3. MICHAL MARJANSKI3,
  4. MARIUSZ WYSOCKI1 and
  5. JAN STYCZYNSKI1
  1. 1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
  2. 2Department of General and Oncological Surgery for Children and Adolescents, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
  3. 3Clinical Oncology Department, Oncology Center, Bydgoszcz, Poland
  1. Correspondence to: Agata Marjanska, MD, Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Antoni Jurasz University Hospital No. 1, ul. Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland. Tel: +48 525854860, Fax: +48 525854087, e-mail: agata.marjanska{at}wp.pl
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 39, Issue 7
July 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
AGATA MARJANSKA, PRZEMYSLAW GALAZKA, MICHAL MARJANSKI, MARIUSZ WYSOCKI, JAN STYCZYNSKI
Anticancer Research Jul 2019, 39 (7) 3945-3947; DOI: 10.21873/anticanres.13547

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
AGATA MARJANSKA, PRZEMYSLAW GALAZKA, MICHAL MARJANSKI, MARIUSZ WYSOCKI, JAN STYCZYNSKI
Anticancer Research Jul 2019, 39 (7) 3945-3947; DOI: 10.21873/anticanres.13547
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Nivolumab for the Treatment of Advanced Pediatric Malignancies
  • Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma
  • Google Scholar

More in this TOC Section

  • Preoperative Risk Analysis for Postoperative Recurrence in Locally Advanced Rectal Cancer Following Chemoradiotherapy
  • Efficacy and Safety of Robotic Surgery for Bulky Colorectal Tumors
  • Comparative Analysis of Dynamic Conformal Arc Therapy and Volumetric-modulated Arc Therapy in Lung Stereotactic Body Radiation Therapy: Evaluating Dosimetric Performance, Treatment Delivery Efficiency, and Plan Robustness
Show more Clinical Studies

Similar Articles

Keywords

  • pembrolizumab
  • malignant melanoma
  • immunotherapy
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire